{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:21:40Z","timestamp":1776784900266,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.semarthrit.2017.03.003","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T19:30:36Z","timestamp":1489001436000},"page":"281-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab"],"prefix":"10.1016","volume":"47","author":[{"given":"Marie-L\u00e9a","family":"Gauci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Laly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Da Meda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.03.003_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma","volume":"73","author":"Ivashko","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib3","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.1985.03360190069027","article-title":"Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome","volume":"254","author":"McCarty","year":"1985","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","article-title":"Paraneoplastic syndromes in rheumatology","volume":"10","author":"Manger","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0022-3859.147038","article-title":"Syndrome of remitting seronegative symmetrical synovitis with pitting edema: a case series","volume":"61","author":"Varshney","year":"2015","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.57.7.442","article-title":"Lack of association between HLA DRB1* alleles and RS3PE syndrome","volume":"57","author":"Toussirot","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and Safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the Anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib9","first-page":"2","article-title":"A case of arthritis under pembrolizumab","author":"Salmon","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib10","first-page":"1","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","author":"Cappelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.39406","article-title":"Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment","volume":"68","author":"De Velasco","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib12","first-page":"2014","article-title":"Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma","author":"Dasanu","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Concise communication","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib14","first-page":"1","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","author":"Garel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib15","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib17","first-page":"763","article-title":"Association of programmed cell death-1 (PDCD-1) gene polymorphisms with rheumatoid arthritis in Iranian patients","volume":"29","author":"Tahoori","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00393-014-1415-y","article-title":"Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility","volume":"74","author":"Lee","year":"2015","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.003_bib19","doi-asserted-by":"crossref","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216303614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216303614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:55:29Z","timestamp":1536000929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216303614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0049017216303614"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}